Form 4: SOPHiA GENETICS: Executive Receives Equity Awards

SOPHiA GENETICS SA reports on equity awards granted to Chief Legal Officer Daan van Well, including restricted stock units and share options.

Summary

• Daan van Well, Chief Legal Officer at SOPHiA GENETICS SA, received a grant of 97,536 restricted stock units (RSUs) on April 2, 2026.
• These RSUs are part of the Issuer's 2021 Equity Incentive Plan and vest over time, with 25% vesting on April 2, 2027, and the remainder vesting quarterly through April 2, 2030.
• Additionally, Mr. van Well was granted a share option to acquire 142,216 ordinary shares.
• This option vests 25% on April 2, 2027, with the remaining portion vesting monthly through April 2, 2030.
• The share option has an exercise price of $5.04.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine executive compensation and does not contain new financial performance data or strategic shifts.

Positives

• Grant of equity awards (RSUs and share options) to a key executive, indicating continued investment in management and potential alignment of interests with shareholders.
• The vesting schedule for both RSUs and options is spread over several years, encouraging long-term retention and performance.
• The share option has a defined exercise price, providing a clear potential upside for the executive.

Negatives

• The filing does not provide details on the valuation of the RSU grant or the potential value of the share options.
• No specific performance metrics are tied to the vesting of these awards, beyond continued service.

Risks

• The value of the RSUs and share options is subject to the future performance of SOPHiA GENETICS SA's stock price.
• If the company's stock price does not appreciate or declines, the value of these equity awards could be significantly diminished.
• Vesting is contingent on continued employment, meaning any departure before vesting dates would result in forfeiture of unvested awards.

Future Outlook

The future outlook for the granted equity awards is dependent on the company's stock performance and the executive's continued service through the vesting periods ending in 2030.

Industry Context

StockSavvy.ai notes that the granting of equity awards, such as RSUs and stock options, to key executives is a common practice in the biotechnology and healthcare technology sectors to incentivize long-term performance and align executive interests with shareholder value.

Stakeholder Impact

• Shareholders: The equity awards align executive interests with long-term shareholder value creation, but the dilutive effect of option exercises should be considered.
• Employees: The granting of equity to senior management can be seen as a positive sign of company stability and growth potential, potentially boosting overall employee morale.
• Management: The awards provide potential financial upside for the Chief Legal Officer, contingent on continued service and company performance.

Next Steps

• Continued vesting of RSUs and share options according to the schedule through April 2, 2030.
• Potential exercise of vested share options by the reporting person.

Key Dates

Keywords

SOPHiA GENETICS SA, Form 4, Equity Awards, Restricted Stock Units, Share Options, Executive Compensation, Insider Trading, SEC Filing, Stock Vesting, Chief Legal Officer